Cargando…
2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016
BACKGROUND: The dissemination of multi-drug-resistant Enterobacteriaceae (MDR Eba) threatens the treatment of Gram-negative infections. Ceftazidime–avibactam (CAZ-AVI) is a novel antimicrobial with activity against Eba producing Class A, C and some Class D β-lactamases. This study evaluates the in v...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255069/ http://dx.doi.org/10.1093/ofid/ofy210.2101 |
_version_ | 1783373871934603264 |
---|---|
author | Estabrook, Mark Kazmierczak, Krystyna Stone, Gregory G Sahm, Dan |
author_facet | Estabrook, Mark Kazmierczak, Krystyna Stone, Gregory G Sahm, Dan |
author_sort | Estabrook, Mark |
collection | PubMed |
description | BACKGROUND: The dissemination of multi-drug-resistant Enterobacteriaceae (MDR Eba) threatens the treatment of Gram-negative infections. Ceftazidime–avibactam (CAZ-AVI) is a novel antimicrobial with activity against Eba producing Class A, C and some Class D β-lactamases. This study evaluates the in vitro activity of CAZ-AVI against Eba isolates from urinary tract infections (UTI), intra-abdominal infections (IAI) and lower respiratory tract infections (LRTI) gathered in Latin America (LA) from 2012 to 2016. METHODS: A total of 7,037 non-duplicate Eba were collected from UTI, IAI, or LRTI in 26 sites in 6 countries in LA, as a part of the INFORM surveillance study from 2012 to 2016. Susceptibility testing was by broth microdilution using CLSI 2018 breakpoints. CAZ-AVI was tested with a fixed concentration of 4 µg/mL avibactam. Meropenem nonsusceptibility prompted β-lactamase screening by PCR and sequencing. RESULTS: CAZ-AVI demonstrated potent in vitro activity against Eba from UTIs, IAIs and LRTIs (99.6%, 99.8%, and 99.5% susceptible, respectively). CAZ-AVI was active against colistin-resistant and MDR Eba as well as meropenem-non-susceptible Eba not encoding metallo-β-lactamases (96.5%, 98.4% and 99.4% susceptible, respectively) (table). CONCLUSION: CAZ-AVI exhibited potent in vitro activity against Eba from UTIs, IAIs and LRTIs isolated in Latin America from 2012 to 2016 and provides a vital alternative to colistin and meropenem when MBLs are not present. DISCLOSURES: M. Estabrook, Pfizer, Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. K. Kazmierczak, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. G. G. Stone, Pfizer Inc.: Employee, Salary. AstraZeneca: Former Employee and Shareholder, Salary. D. Sahm, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. |
format | Online Article Text |
id | pubmed-6255069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62550692018-11-28 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016 Estabrook, Mark Kazmierczak, Krystyna Stone, Gregory G Sahm, Dan Open Forum Infect Dis Abstracts BACKGROUND: The dissemination of multi-drug-resistant Enterobacteriaceae (MDR Eba) threatens the treatment of Gram-negative infections. Ceftazidime–avibactam (CAZ-AVI) is a novel antimicrobial with activity against Eba producing Class A, C and some Class D β-lactamases. This study evaluates the in vitro activity of CAZ-AVI against Eba isolates from urinary tract infections (UTI), intra-abdominal infections (IAI) and lower respiratory tract infections (LRTI) gathered in Latin America (LA) from 2012 to 2016. METHODS: A total of 7,037 non-duplicate Eba were collected from UTI, IAI, or LRTI in 26 sites in 6 countries in LA, as a part of the INFORM surveillance study from 2012 to 2016. Susceptibility testing was by broth microdilution using CLSI 2018 breakpoints. CAZ-AVI was tested with a fixed concentration of 4 µg/mL avibactam. Meropenem nonsusceptibility prompted β-lactamase screening by PCR and sequencing. RESULTS: CAZ-AVI demonstrated potent in vitro activity against Eba from UTIs, IAIs and LRTIs (99.6%, 99.8%, and 99.5% susceptible, respectively). CAZ-AVI was active against colistin-resistant and MDR Eba as well as meropenem-non-susceptible Eba not encoding metallo-β-lactamases (96.5%, 98.4% and 99.4% susceptible, respectively) (table). CONCLUSION: CAZ-AVI exhibited potent in vitro activity against Eba from UTIs, IAIs and LRTIs isolated in Latin America from 2012 to 2016 and provides a vital alternative to colistin and meropenem when MBLs are not present. DISCLOSURES: M. Estabrook, Pfizer, Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. K. Kazmierczak, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. G. G. Stone, Pfizer Inc.: Employee, Salary. AstraZeneca: Former Employee and Shareholder, Salary. D. Sahm, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. Oxford University Press 2018-11-26 /pmc/articles/PMC6255069/ http://dx.doi.org/10.1093/ofid/ofy210.2101 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Estabrook, Mark Kazmierczak, Krystyna Stone, Gregory G Sahm, Dan 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016 |
title | 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016 |
title_full | 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016 |
title_fullStr | 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016 |
title_full_unstemmed | 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016 |
title_short | 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016 |
title_sort | 2448. in vitro activity of ceftazidime–avibactam against enterobacteriaceae causing intra-abdominal, urinary tract and lower respiratory tract infections collected in latin america as part of the inform global surveillance program, 2012–2016 |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255069/ http://dx.doi.org/10.1093/ofid/ofy210.2101 |
work_keys_str_mv | AT estabrookmark 2448invitroactivityofceftazidimeavibactamagainstenterobacteriaceaecausingintraabdominalurinarytractandlowerrespiratorytractinfectionscollectedinlatinamericaaspartoftheinformglobalsurveillanceprogram20122016 AT kazmierczakkrystyna 2448invitroactivityofceftazidimeavibactamagainstenterobacteriaceaecausingintraabdominalurinarytractandlowerrespiratorytractinfectionscollectedinlatinamericaaspartoftheinformglobalsurveillanceprogram20122016 AT stonegregoryg 2448invitroactivityofceftazidimeavibactamagainstenterobacteriaceaecausingintraabdominalurinarytractandlowerrespiratorytractinfectionscollectedinlatinamericaaspartoftheinformglobalsurveillanceprogram20122016 AT sahmdan 2448invitroactivityofceftazidimeavibactamagainstenterobacteriaceaecausingintraabdominalurinarytractandlowerrespiratorytractinfectionscollectedinlatinamericaaspartoftheinformglobalsurveillanceprogram20122016 |